Greater Effect of Enhanced Pharmacist Care on Cholesterol Management in Patients with Diabetes Mellitus: A Planned Subgroup Analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP)

Study Objective. To determine the effect of enhanced pharmacist care on cholesterol management in patients with and without diabetes mellitus.

[1]  S. Majumdar,et al.  Compliance with Clinical Practice Guidelines for Type 2 Diabetes in Rural Patients: Treatment Gaps and Opportunities for Improvement , 2003, Pharmacotherapy.

[2]  Richard W Grant,et al.  Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. , 2002, The American journal of medicine.

[3]  K. Teo,et al.  A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). , 2002, Archives of internal medicine.

[4]  M. Ravid,et al.  Teaching patients to monitor their risk factors retards the progression of vascular complications in high‐risk patients with Type 2 diabetes mellitus—a randomized prospective study , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[5]  H. Keen,et al.  Mortality and causes of death in the WHO multinational study of vascular disease in diabetes , 2001, Diabetologia.

[6]  A. Boulton,et al.  Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. , 2001, Diabetes care.

[7]  Jeffrey A. Johnson,et al.  Economic Impact of Community Pharmacist Intervention in Cholesterol Risk Management: An Evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists , 2001, Pharmacotherapy.

[8]  J. Frohlich,et al.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[9]  K. Teo,et al.  Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): A Randomized Trial Design of the Effect of a Community Pharmacist Intervention Program on Serum Cholesterol Risk , 1999, The Annals of pharmacotherapy.

[10]  N. Poulter,et al.  The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population‐based analysis from the Health Surveys for England 1991–94 , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[11]  I. U. Haq,et al.  Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men , 1999, Heart.

[12]  Ian Graham,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.

[13]  M. Harris,et al.  Mortality in Adults With and Without Diabetes in a National Cohort of the U.S. Population, 1971–1993 , 1998, Diabetes Care.

[14]  P. O S I T I O N S T A T E M E N T.  Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.

[15]  M. Mullee,et al.  Mortality Rates in Diabetic Patients from a Community‐based Population Compared to Local Age/Sex Matched Controls , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[16]  I Cikes,et al.  [Prevention of coronary heart disease in clinical practice]. , 1996, Lijecnicki vjesnik.

[17]  C. Woodward,et al.  Preventive care and barriers to effective prevention. How do family physicians see it? , 1996, Canadian family physician Medecin de famille canadien.

[18]  Janzen,et al.  The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. , 1996, The Canadian journal of cardiology.

[19]  D. Maclean,et al.  Epidemiology of diabetes mellitus in Canada. , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

[20]  S. Gardner,et al.  Community Pharmacy Data Bases to Identify Patients at High Risk for Hypercholesterolemia , 1995, Pharmacotherapy.

[21]  D. M. Elnicki,et al.  Patient-perceived barriers to preventive health care among indigent, rural Appalachian patients. , 1995, Archives of internal medicine.

[22]  K. Donato,et al.  Lipids. Workshop IV. AHA Prevention Conference III. Behavior change and compliance: keys to improving cardiovascular health. , 1993, Circulation.

[23]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[24]  J. Cornfield,et al.  A multivariate analysis of the risk of coronary heart disease in Framingham. , 1967, Journal of chronic diseases.

[25]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[26]  Andrew,et al.  Peripheral Arterial Disease in Diabetic and Nondiabetic Patients , 2001 .

[27]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[28]  Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. The Clinical Quality Improvement Network (CQIN) Investigators. , 1995, The American journal of cardiology.

[29]  E. Barrett-Connor,et al.  Clustering of heart disease risk factors in diabetic compared to nondiabetic adults. , 1983, American journal of epidemiology.